# Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis

> **NCT00184366** · — · TERMINATED · sponsor: **Norwegian University of Science and Technology** · enrollment: 96 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** efalizumab

## Key facts

- **NCT ID:** NCT00184366
- **Lead sponsor:** Norwegian University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** 2008-05
- **Final completion:** 2008-07
- **Target enrollment:** 96 (ACTUAL)
- **Why stopped:** efalizumab was withdrawn from market; full 2 years follow-up only 14 patients
- **Last updated:** 2012-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00184366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00184366, "Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00184366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*